AU Patent

AU2014302122B2 — Stable liquid formulation of AMG 416 (Velcalcetide)

Assigned to Amgen Inc · Expires 2018-12-06 · 7y expired

What this patent protects

A liquid formulation comprising a peptide agonist of the calcium sensing receptor and method of preparing and using the formulation are provided.

USPTO Abstract

A liquid formulation comprising a peptide agonist of the calcium sensing receptor and method of preparing and using the formulation are provided.

Drugs covered by this patent

Patent Metadata

Patent number
AU2014302122B2
Jurisdiction
AU
Classification
—
Expires
2018-12-06
Drug substance claim
No
Drug product claim
No
Assignee
Amgen Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.